A new Actemra (tocilizumab) indication for an adverse event associated with chimeric antigen receptor T-cell therapy resulted from an unusual collaboration between product sponsor Genentech Inc., the two leading CAR-T product developers, and the US FDA, which showed a high degree of flexibility as to the source and type of data sufficient to support the new claim.
On Aug